Navigation Links
Structural Genomics Consortium releases 1,000th protein structure
Date:9/28/2010

The Structural Genomics Consortium (SGC), an international public-private partnership that aims to determine three dimensional structures of medically important proteins, announced today the release into the public domain of its 1000th high resolution protein structure.

The 1000th structure known as JmjD2C belongs to a class of proteins involved in epigenetic signalling, a key research area for the SGC. Epigenetics is the study of inherited changes in gene expression caused by proteins such as JmjD2C which 'switch' genes on or off. It is believed that a better understanding of epigenetics could lead to new treatments for a wide variety of diseases including cancer, diabetes, obesity and many psychiatric diseases.

"JmjD2C is already known to play a key a role in the maintenance of self renewal in stem cells as well as roles in cancer," says Professor Udo Oppermann of SGC Oxford, who led the team solving the 1000th structure. "Now that its 3D structure is in the public domain, we hope that this will spur other scientists to investigate its functions more deeply and understand more clearly its role in epigenetics."

"This milestone reinforces the advantages of open-innovation partnerships between the public and private sectors," says Dr Aled Edwards the SGC Chief Executive. "We're extremely proud of this achievement and the efforts of our co-workers and their collaborators around the world."

Formed in 2004, the SGC comprises 180 scientists at labs at the Universities of Oxford and Toronto, and the Karolinska Institutet in Stockholm. The international collaboration is supported by public and private sector funding. All research output is made available to the research community free from restriction on use and protein structures are deposited in the Protein Data Bank (PDB). In 2009, the SGC contributed nearly a third of all new human proteins structures deposited in the PDB, and a similar fraction of protein structures fr
'/>"/>

Contact: Craig Brierley
c.brierley@wellcome.ac.uk
44-207-611-7329
Wellcome Trust
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Pitt/Iowa team finds cellular structural molecule can be toxic: Makes pneumonia worse
2. Structural defects precede functional decline in heart muscle
3. University of Nevada professor studies structural basis for autism disorders
4. National Science Foundation awards grant to Oklahoma structural biology group
5. National Science Foundations awards grant to Oklahoma structural biology group
6. Structural biology scores with protein snapshot
7. NIH expands key pharmacogenomics resource
8. Paper offers new insights into the genomics of speciation
9. Symposium spotlights new paradigms in genomics, celebrates AIDS-fighting drug at 25 years
10. MIT student inventor honored for transformative work in genomics and linguistics
11. The impact of genomics
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Structural Genomics Consortium releases 1,000th protein structure
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... by the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore ... key protein linked to stem cell-like behavior in terminal-stage ... drugs that may extend the survival of these patients. ... Proceedings of the National Academy of Sciences , ...
... to reduce by more than half the time it takes ... researchers in Penn State,s College of Agricultural Sciences. The finding ... foodborne illness, allowing epidemiological investigators to identify the exact strains ... more quickly find -- and eliminate -- the source of ...
... long been used for various purposes, like cleaning wastewater at ... handcrafted wickerwork, as means of nutrition and, in traditional medicine, ... Fraunhofer Institute for Building Physics IBP in Valley now want ... to wit, for the insulation of outer walls or ...
Cached Biology News:Singapore research team identifies new drug target in deadly form of leukemia 2Researchers develop a faster method to identify Salmonella strains 2Researchers develop a faster method to identify Salmonella strains 3Using cattails for insulation 2Using cattails for insulation 3
(Date:4/24/2015)... 24, 2015 The South Dakota School ... have entered into an agreement to promote cooperation on ... agreement signed by the universities will encourage and promote ... other services particularly, though not exclusively, relating to sustainability, ... strengths and a similar set of values,” said Michael ...
(Date:4/24/2015)...  Pfenex Inc. (NYSE MKT: PFNX) a clinical-stage biotechnology ... high value and difficult to manufacture proteins, today announced ... shares of its common stock at a price to ... being offered, 2,610,000 are being offered by Pfenex and ... stockholders. Pfenex will not receive any proceeds from the ...
(Date:4/24/2015)... Seoul Semiconductor announced the expansion of ... the lighting market. In recent months, there ... in emerging markets such as Russia, South America, ... applications such as streetlight and area lighting, tunnel ... launched in 2005 the Acrich technology from Seoul ...
(Date:4/23/2015)... , April 23, 2015 /CNW/ - A new and ... award from North America,s ... Comparison won Silver in the "Sustainability, service" category ... The Brandcheck "Competitor Comparison" is a service that ... American and Global peers. This benchmarking process shows ...
Breaking Biology Technology:South Dakota Mines, Arizona State University Pave Way for Cooperative Research 2Pfenex Inc. Announces Pricing Of Follow-on Offering 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2
... Scientists engaged in biological research and drug discovery are ... BioInformatics, LLC ( www.gene2drug.com ), the premier research ... released preliminary data from the company,s newest report ... Science Suppliers. In this report, we set out ...
... LOUIS, Feb. 11 Sigma-Aldrich, a leading Life,Science and High ... by 6% to $0.68 from $0.64 in the same quarter ... $510 million in the fourth quarter 2008 declined by 4%,compared ... fourth,quarter grew 3% from a year ago. Fourth quarter organic ...
... Development for Chronic Pain IndicationsLA JOLLA, Calif., Feb. ... TPTX ) today announced that oral administration of ... and well-tolerated in healthy male and female subjects ... successful completion of this Phase I trial demonstrating ...
Cached Biology Technology:Life Science Labs Reacting to the Economic Crisis 2Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 2Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 3Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 4Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 5Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 6Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 7Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 8Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 9Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 10Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 11Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 12Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 13First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 2First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 3First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 4
ELF® 97 Immunohistochemistry Kit...
albumin from bovine serum (BSA), Alexa Fluor® 647 conjugate...
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed. Free windows version for academic use....
... bovine, porcine, rat) ... antagonist. This carboxy-terminal VIP fragment ... more potent than any previously ... Storage: Desiccate ...
Biology Products: